Global Cancer Profiling Market to Reach USD 16.0 Billion by 2027

 The global cancer profiling market is undergoing rapid transformation, powered by breakthroughs in genomics, biomarker discovery, and precision oncology. Valued at USD 9.7 billion in 2022, the market is projected to reach USD 16.0 billion by 2027, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period.

This remarkable growth reflects the rising investment in cancer research, increasing adoption of advanced molecular diagnostics, and a global shift toward personalized medicine—a treatment approach tailored to an individual’s genetic makeup.



Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202

🌎 Market Overview

Cancer profiling, also known as tumor profiling, involves the analysis of genetic, epigenetic, and proteomic alterations in cancer cells. It helps clinicians identify specific biomarkers that drive tumor growth and predict a patient’s response to targeted therapies.

According to recent market insights, North America currently leads the global cancer profiling market due to high research funding, strong biotechnology infrastructure, and the presence of major players such as Illumina, Thermo Fisher Scientific, QIAGEN, and Foundation Medicine.

🚀 Key Market Drivers

1. Increasing Use of Biomarkers in Cancer Profiling

Over the past decade, biomarker development in oncology has revolutionized the understanding of cancer mechanisms. Biomarkers—molecules that indicate the presence or stage of cancer—enable early detection, personalized treatment selection, and monitoring of therapeutic response.

As molecular diagnostics and biomarker discoveries accelerate, researchers and pharmaceutical companies are integrating biomarkers into clinical trials and therapeutic decision-making. This is a major factor driving the adoption of cancer profiling technologies globally.

2. Technological Advancements in Profiling

The rise of next-generation sequencing (NGS) and mass spectrometry technologies has allowed scientists to explore complex genetic alterations across multiple cancer types. NGS, in particular, is expected to register the highest growth rate among all technologies, offering deep insights into cancer genomics and identifying novel therapeutic targets.

3. Growing Focus on Personalized Medicine

The shift from “one-size-fits-all” therapies to precision oncology is transforming cancer care. Tumor genomic profiling enables oncologists to tailor treatments to the unique genetic profile of each patient. This trend is expected to drive demand for cancer profiling solutions across hospitals, research institutions, and pharmaceutical companies.

⚠️ Market Challenges

1. High Capital Investment for Biomarker Development

While biomarker research is advancing rapidly, it remains a costly and time-consuming process. Validation, regulatory approval, and clinical adoption require significant funding. These high costs often translate into expensive diagnostic tests, limiting accessibility in developing regions.

2. Low Biomarker Discovery-to-Approval Ratio

Despite the identification of thousands of candidate biomarkers, only a small fraction successfully reach clinical use. Many biomarkers fail during validation due to lack of reproducibility or insufficient specificity. This bottleneck continues to challenge the industry, emphasizing the need for robust validation frameworks and improved regulatory clarity.

💡 Market Opportunities

Growing Adoption of Point-of-Care and Personalized Diagnostics

The integration of point-of-care testing (POCT) in oncology is gaining momentum. Portable diagnostic solutions powered by genomics and AI are making cancer profiling faster and more accessible. Furthermore, the global emphasis on personalized medicine creates new opportunities for companies developing tailored diagnostic tools and therapeutics.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=202

🔍 Segment Insights

By Technology

  • Next-Generation Sequencing (NGS): Expected to grow at the highest CAGR due to its ability to explore complex genetic variations and discover novel biomarkers.
  • PCR, Immunoassays, Microarrays, and Mass Spectrometry continue to be widely used for targeted profiling and biomarker validation.

By Cancer Type

  • Breast Cancer accounted for the largest market share in 2021, attributed to high disease prevalence and extensive R&D collaborations.
  • Lung, prostate, colorectal, and melanoma cancers are also key focus areas for tumor profiling technologies.

By Biomarker Type

  • Genomic biomarkers dominate the market, providing essential information for precision therapies and early disease detection.
  • Protein biomarkers follow closely, aiding in diagnostics and therapeutic monitoring.

By Application

  • Biomarker discovery leads the research segment, driven by pharmaceutical R&D and drug development efforts.
  • Personalized medicine and diagnostics form the core of clinical applications, enhancing treatment outcomes and reducing side effects.

🌍 Regional Analysis

North America

Holds the largest share of the global cancer profiling market due to robust R&D infrastructure, widespread adoption of precision diagnostics, and strong government and private funding initiatives.

Europe

Expected to witness steady growth with increasing clinical adoption of molecular profiling and regulatory support for companion diagnostics.

Asia Pacific

Emerging as a fastest-growing region, driven by rising cancer incidence, expanding healthcare infrastructure, and supportive government programs in countries such as China, Japan, and India.

🧬 Recent Industry Developments

  • May 2022: QIAGEN launched the therascreen EGFR Plus RGQ PCR Kit to enhance non-small cell lung cancer (NSCLC) diagnostics.
  • January 2022: Illumina partnered with Agendia to advance next-generation sequencing for decentralized oncology testing, empowering personalized breast cancer treatment.
  • June 2021: NeoGenomics, Inc. acquired Inivata Ltd., strengthening its liquid biopsy and molecular diagnostic portfolio.

🏢 Key Market Players

Leading companies shaping the global cancer profiling landscape include:
Illumina, Inc. (US) | QIAGEN N.V. (Germany) | NeoGenomics, Inc. (US) | Sysmex Corporation (Japan) | HTG Molecular Diagnostics, Inc. (US) | Caris Life Sciences (US) | NanoString Technologies, Inc. (US) | Guardant Health, Inc. (US) | Foundation Medicine (US) | F. Hoffmann-La Roche Ltd. (Switzerland) | Thermo Fisher Scientific Inc. (US) | Genscript Biotech Corporation (US) | Tempus Labs (US) | Hologic, Inc. (US)

🧠 Conclusion

The global cancer profiling market is at the forefront of the precision medicine revolution. With continuous technological innovation, growing biomarker adoption, and strategic industry collaborations, cancer profiling is redefining how we diagnose, monitor, and treat cancer.

As investments surge and genomic research advances, the next five years are expected to bring unprecedented opportunities for market players — ultimately leading to earlier detection, better treatment decisions, and improved patient outcomes worldwide.

 

Comments

Post a Comment

Popular posts from this blog

Urology Devices Industry worth $48.6 billion by 2028

 The global urology devices market , valued at US$32.6 billion in 2022, is forecasted to grow at a robust CAGR of 7.3%, reaching US$34.1 billion in 2023 and an impressive US$48.6 billion by 2028. Investments by hospitals in procuring advanced instruments, expanding units, and establishing new centers are expected to boost the market for urology devices. Moreover, increased demand for MIS robotic systems is expected to increase in the coming years, which is expected to propel the market growth. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212 Browse in-depth TOC on “Urology Devices Market” 159 — Tables 44 — Figures 274 — Pages In 2022, the instruments segment held the largest share of the urology devices market by product segment. The urology devices market is segmented into instruments and consumables & accessories based on products. The instruments segment accounted for the largest share of the urology devices market in 2022....
Read more

Adhesion Barrier Industry worth $0.9 billion by 2028, with a CAGR of 7.4%

  The report   " Adhesion Barrier Market  by Product (Regenerated Cellulose, Hyaluronic Acid, PEG), Type (Film, Gel, Liquid), Procedure (Abdominal, Cardiovascular, Gynae, Neurology), End User (Hospitals, Clinics & ASC), Region- Global Forecast to 2028" , is valued at an estimated USD 0.7 billion in 2023 and is projected to reach USD 0.9 billion by 2028, at a CAGR of 7.4% during the forecast period. The main drivers of this market's expansion are the rising number of surgeries and sports-related injuries, an increasing elderly population, and a growing understanding by of the adhesion formation and health issues linked to adhesions. On the other hand, during the forecast period, it is projected that surgeons' resistance to using adhesion barriers will impede market expansion. Browse 207 market data Tables and 50 Figures spread through 238 Pages and in-depth TOC on  "Adhesion Barrier Market by Product (Regenerated Cellulose, Hyaluronic Acid, PEG), Type (F...
Read more

Healthcare Simulation Market worth $4.6 billion by 2028

Image
The global healthcare simulation market is projected to reach USD 4.6 billion by 2028 from USD 2.2 billion in 2023, at a high CAGR of 15.7% during the forecast period. The market's expansion is fuelled by an advancement in technology, such as high-fidelity manikins and virtual reality that have enhanced the realism and effectiveness of simulation training, for instance, high-fidelity simulators like Apollo (by Elevate Healthcare (formerly CAE)) and Nursing Anne Simulator (by Laerdal Medical) accelerates learning, reduces training time, and improves debriefing with automated patient responses; the growing complexity of modern medical procedures which requires training solutions offered by simulation. Further, the increasing number of medical schools is also propelling this market. For instance, according to Ministry of Health and Family Welfare, in India, the number of medical colleges has risen by 82%, from 387 before 2014 to 706 for the year 2024. Healthcare Simulation Market – G...
Read more